A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib

• Main Authors: Ling Gao (Author), Ikuo Yamamiya (Author), Mark Pinti (Author), Juan Carlos Rondon (Author), Thomas Marbury (Author), Gareth Tomlinson (Author), Lukas Makris (Author), Nanae Hangai (Author), Volker Wacheck (Author)
• Format: Book
• Published: Wiley, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Futibatinib is a covalently binding FGFR1-4 inhibitor that received US Food and Drug Administration approval for the treatment of patients with previously treated, advanced intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions/rearrangements. This phase I trial evaluated the pharmaco...